Search results for "Lua"

showing 10 items of 3286 documents

Quand les diplômés de doctorats français partis à l'étranger autoévaluent leurs compétences

2017

International audience; Cette recherche propose de s'interroger sur le périmètre des compétences scientifiques et non scientifiques des doctorants, ce que Bozeman et Corley (2004) définissent comme le capital humain scientifique et technique spécifique au milieu de la recherche et de l'innovation. Ces compétences ne sont pas homogènes et peuvent traduire la diversité des situations d'apprentissage en cours de thèse, en fonction notamment de l'environnement des doctorants. Certaines seront strictement scientifiques alors que d'autres, plus transversales à des activités non scientifiques, ont pu se développer tout au long du doctorat. L'objectif plus précis de cette recherche est de savoir da…

Docteur[SHS.EDU]Humanities and Social Sciences/EducationMobilité internationale[SHS.EDU] Humanities and Social Sciences/Education[ SHS.EDU ] Humanities and Social Sciences/EducationFranceAuto-évaluationCompétenceEnseignement supérieur
researchProduct

Une évaluation des effets du dispositif Jeunes docteurs sur l'accès aux emplois de RD

2018

DocteurÉvaluation d'un dispositifJeune travailleurAccès à l'emploiInsertion professionnelle[SHS.EDU] Humanities and Social Sciences/EducationRD
researchProduct

The new 5- or 6-azapyrimidine and cyanuric acid derivatives of L-ascorbic acid bearing the free C-5 hydroxy or C-4 amino group at the ethylenic space…

2011

Abstract We report on the synthesis of the novel types of cytosine and 5-azacytosine (1–9), uracil and 6-azauracil (13–18) and cyanuric acid (19–22) derivatives of l -ascorbic acid, and on their cytostatic activity evaluation in human malignant tumour cell lines vs. their cytotoxic effects on human normal fibroblasts (WI38). The CD spectra analysis revealed that cytosine (5 and 6), uracil (14–16), 6-azauracil (17) and cyanuric acid (21) derivatives of l -ascorbic acid bearing free amino group at ethylenic spacer existed as a racemic mixture of enantiomers, whereas L-ascorbic derivatives containing the C-5 substituted hydroxy group at the ethylenic spacer were obtained in (4R, 5S) enantiomer…

Double bondStereochemistryAscorbic AcidCrystallography X-Ray010402 general chemistry01 natural sciencesCell LineCytosineInhibitory Concentration 50Structure-Activity Relationship03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DiscoveryHumansUracilta116Pharmacologychemistry.chemical_classificationTriazinespyrimidine and cyanuric acid derivatives; L-ascorbic acid; circular dichroism; cytostatic activity evaluation; X-ray diffractionOrganic ChemistryAbsolute configurationHydrogen BondingStereoisomerismUracilBiological activityHep G2 CellsGeneral MedicineFibroblastsCytostatic AgentsAscorbic acidpyrimidine and cyanuric acid derivatives ; L-ascorbic acid ; circular dichroism ; cytostatic activity evaluation ; X-ray diffraction ; cell cycle analysis0104 chemical sciences3. Good healthchemistry030220 oncology & carcinogenesisS Phase Cell Cycle CheckpointsMCF-7 CellsCyanuric acidCytosineLactoneHeLa Cells
researchProduct

Chemical composition and antimicrobial activity of the essential oils of some species of Anthemis sect. Anthemis (Asteraceae) from Sicily

2017

The chemical composition of the essential oils isolated from the aerial parts of Anthemis arvensis L. subsp. arvensis, Anthemis cretica subsp. messanensis (Brullo) Giardina & Raimondo and from flowers and leaves of Anthemis cretica subsp. columnae (Ten.) Frezén were determinated by GC–FID and GC–MS analyses. Torreyol (85.4%) was recognised as the main constituent of the Anthemis arvensis subsp. arvensis essential oil, while in the essential oils of Anthemis cretica subsp. messanensis, collected on the rock and cultivated in Hortus Botanicus Panormitanus, (E)-chrysanthenyl acetate (28.8 and 24.2% resp.), 14-hydroxy-α-humulene (8.1 and 5.3% resp.), santolina triene (8 and 5.8% resp.) and …

Drug Evaluation PreclinicalRaimondoAnthemis arvensisFlowersMicrobial Sensitivity TestsPlant Science01 natural sciencesBiochemistryGas Chromatography-Mass Spectrometryessential oillaw.inventionAnalytical Chemistrychemistry.chemical_compoundBridged Bicyclo CompoundsAnti-Infective Agentsantibacterial activitylawSantolinaBotanyOils VolatileAnthemisSettore BIO/15 - Biologia FarmaceuticaChemical compositionSicilyAnthemis arvensis L. subsp. arvensiEssential oiltorreyolBicyclic MonoterpenesPolycyclic Sesquiterpenesalpha-PineneEucalyptolbiology010405 organic chemistryOrganic ChemistryAnthemis cretica subsp. columnae (Ten.) FrezénAsteraceaebiology.organism_classificationCyclohexanols0104 chemical sciencesPlant Leaves010404 medicinal & biomolecular chemistryEucalyptolchemistryMonoterpenesAnthemis cretica subsp. messanensis (Brullo) Giardina &ampAnthemisSesquiterpenes
researchProduct

New antitrichomonal drug-like chemicals selected by bond (edge)-based TOMOCOMD-CARDD descriptors.

2008

Bond-based quadratic indices, new TOMOCOMD-CARDD molecular descriptors, and linear discriminant analysis (LDA) were used to discover novel lead trichomonacidals. The obtained LDA-based quantitative structure-activity relationships (QSAR) models, using nonstochastic and stochastic indices, were able to classify correctly 87.91% (87.50%) and 89.01% (84.38%) of the chemicals in training (test) sets, respectively. They showed large Matthews correlation coefficients of 0.75 (0.71) and 0.78 (0.65) for the training (test) sets, correspondingly. Later, both models were applied to the virtual screening of 21 chemicals to find new lead antitrichomonal agents. Predictions agreed with experimental resu…

DrugAdultQuantitative structure–activity relationshipStereochemistrymedia_common.quotation_subjectOvariectomyDrug Evaluation PreclinicalTrichomonas InfectionsAntitrichomonal AgentsBiochemistryAnalytical Chemistrychemistry.chemical_compoundIn vivoMolecular descriptorDrug Resistance BacterialTrichomonas vaginalisAnimalsHumansRats Wistarmedia_commonChromatographyMolecular StructureChemistryDiscriminant AnalysisLinear discriminant analysisRatsAntitrichomonal agentEdge basedMolecular MedicineComputer-Aided DesignFemaleSoftwareBiotechnologyJournal of biomolecular screening
researchProduct

Preclinical evidence of new opioid modulators for the treatment of addiction.

2010

Addiction to opiates is one of the most severe forms of substance dependence, and despite a variety of pharmacological approaches to treat it, relapse is observed in a high percentage of subjects. New pharmacological compounds are necessary to improve the outcome of treatments and reduce adverse side effects. Moreover, drugs that act on the opioid system can also be of benefit in the treatment of alcohol or cocaine addiction. AREA COVERED BY THIS REVIEW: Recent preclinical studies of pharmacological agents for the treatment of opiate addiction (2008 to the present date).The reader will be informed of the latest drugs shown in animal models to modify dependence on opiates and the reinforcing…

DrugGABA Agentsmedia_common.quotation_subjectNarcotic AntagonistsDrug Evaluation PreclinicalReceptors Opioid muPharmacologyReceptors NicotinicBioinformaticsPharmacotherapyDopamineReceptors Opioid deltaCannabinoid Receptor ModulatorsmedicineAdrenergic alpha-2 Receptor AgonistsAnimalsPharmacology (medical)Adverse effectmedia_commonPharmacologySubstance dependencebusiness.industryAddictionReceptors Opioid kappaAntagonistGeneral Medicinemedicine.diseaseOpioid-Related DisordersRatsSubstance Withdrawal SyndromeOpioidReceptors OpioidDopamine AntagonistsFemalebusinessExcitatory Amino Acid Antagonistsmedicine.drugExpert opinion on investigational drugs
researchProduct

Covalent binding of drug metabolites to DNA ? a tool of predictive value?

1980

The presently available data suggest at least some correlation between covalent binding of drug metabolites to DNA and carcinogenicity of that drug. More data, however, are needed to establish the predictability of covalent DNA binding assays for extrahepatic cancer. A covalent binding assay requires administration of radioactively labelled compound to the experimental animals; the availability of labelled compound and requirements as to radiochemical purity, chemical and biochemical stability are limiting the applicability of this procedure. Many technical pitfalls accompany covalent DNA binding assays. It is concluded that at the present time DNA binding assays do not represent routine pr…

DrugHealth Toxicology and Mutagenesismedia_common.quotation_subjectLiver NeoplasmsDrug Evaluation PreclinicalCovalent bindingDNAGeneral MedicineIn Vitro TechniquesToxicologyPredictive valueMolecular biologyRatschemistry.chemical_compoundLiverchemistryBiochemistryCovalent bondCarcinogensAnimalsStandard testDNACarcinogenDrug metabolismmedia_commonArchives of Toxicology
researchProduct

Inkjet printing methodologies for drug screening

2010

We show for the first time a contactless, low-cost, and rapid drug screening methodology by employing inkjet printing for molecular dispensing in a microarray format. Picoliter drops containing a model substrate (D-glucose)/ inhibitor (D-glucal) couple were accurately dispensed on a single layer consisting of the enzymatic target (glucose oxidase) covalently linked to a functionalized silicon oxide support. A simple colorimetric detection method allowed one to prove the screening capability of the microarray with the possibility to assay with high reproducibility at the single spot level. Measurements of the optical signal as a function of concentration and of time verified the occurrence a…

DrugReproducibilitybiologyInkwellStereochemistryChemistrymedia_common.quotation_subjectDrug Evaluation PreclinicalNanotechnologySubstrate (printing)Microarray AnalysisSilicon DioxideAnalytical ChemistryGlucose OxidaseSensor arraybiology.proteinColorimetryInkGlucose oxidasedrug screening inkjet printing microarrays biological surfacesEnzyme InhibitorsColorimetryInkjet printingmedia_commonSettore CHIM/02 - Chimica Fisica
researchProduct

Mildronate: An Antiischemic Drug for Neurological Indications

2005

Mildronate (3-(2,2,2-trimethylhydrazinium)propionate; MET-88; meldonium, quaterine) is an antiischemic drug developed at the Latvian Institute of Organic Synthesis. Mildronate was designed to inhibit carnitine biosynthesis in order to prevent accumulation of cytotoxic intermediate products of fatty acid beta-oxidation in ischemic tissues and to block this highly oxygen-consuming process. Mildronate is efficient in the treatment of heart ischemia and its consequences. Extensive evaluation of pharmacological activities of mildronate revealed its beneficial effect on cerebral circulation disorders and central nervous system (CNS) functions. The drug is used in neurological clinics for the trea…

Drugmedia_common.quotation_subjectCentral nervous systemIschemiaStimulationKetone BodiesPharmacologyNitric OxideToxicologyModels BiologicalArticleNitric oxidechemistry.chemical_compoundNeuropharmacologyIschemiamedicineAnimalsHumansReceptormedia_commonPharmacologyMeldoniumbusiness.industryCardiovascular Agentsmedicine.diseaseNeuropsychology and Physiological Psychologymedicine.anatomical_structurechemistryMechanism of actionDrug Evaluationmedicine.symptombusinessmedicine.drugMethylhydrazines
researchProduct

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

2007

The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level.

Drugubiquitin-proteasome pathway proteasome inhibitorsSettore MED/06 - Oncologia Medicamedia_common.quotation_subjectClinical BiochemistryDrug Evaluation PreclinicalAntineoplastic AgentsApoptosisPharmacologyBortezomibNeoplasmsDrug DiscoverymedicineAnimalsHumansMultiple myelomamedia_commonPharmacologyClinical Trials as Topicbusiness.industryBortezomibmedicine.diseaseBoronic AcidsProteasomeClinical evidenceCytoplasmApoptosisPyrazinesProteasome inhibitorMolecular Medicinebusinessmedicine.drug
researchProduct